NYSE:CBM (USA) Also trade in: Germany

Cambrex Corp

$ 41.67 0 (0%)
On watch
Volume: 131,656 Avg Vol (1m): 235,668
Market Cap $: 1.40 Bil Enterprise Value $: 1.83 Bil
P/E (TTM): 17.73 P/B: 2.13
Earnings Power Value 8.77
Net Current Asset Value -13.52
Tangible Book -0.14
Projected FCF 35.97
Median P/S Value 28.09
Graham Number 19.48
Peter Lynch Value 49.07
DCF (FCF Based) 15.89
DCF (Earnings Based) 66.9
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.14
Cash-To-Debt ranked higher than
98.98% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CBM: 0.14
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0, Med: 0.22, Max: 10000
Current: 0.14
0
10000
Equity-to-Asset 0.44
Equity-to-Asset ranked higher than
59.76% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
CBM: 0.44
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.22, Med: 0.48, Max: 0.75
Current: 0.44
0.22
0.75
Debt-to-Equity 0.76
Debt-to-Equity ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
CBM: 0.76
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.1, Med: 0.62, Max: 1.76
Current: 0.76
0.1
1.76
Debt-to-EBITDA 3.24
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
CBM: 3.24
Ranked among companies with meaningful Debt-to-EBITDA only.
N/A
Interest Coverage 11.39
Interest Coverage ranked lower than
71.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
CBM: 11.39
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 5.13, Med: 23.42, Max: 184.18
Current: 11.39
5.13
184.18
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.33
DISTRESS
GREY
SAFE
Beneish M-Score -0.88
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 12.43%
WACC 14.97%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 19.67
Operating Margin ranked higher than
91.16% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
CBM: 19.67
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 9.32, Med: 14.84, Max: 27.02
Current: 19.67
9.32
27.02
Net Margin % 14.31
Net Margin ranked higher than
89.77% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
CBM: 14.31
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 4.25, Med: 14.25, Max: 22.53
Current: 14.31
4.25
22.53
ROE % 12.35
ROE ranked higher than
93.73% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CBM: 12.35
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 9.15, Med: 17.89, Max: 47.26
Current: 12.35
9.15
47.26
ROA % 7.05
ROA ranked higher than
95.20% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CBM: 7.05
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 2.74, Med: 10.47, Max: 17.1
Current: 7.05
2.74
17.1
ROC (Joel Greenblatt) % 20.61
ROC (Joel Greenblatt) ranked higher than
91.41% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CBM: 20.61
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 11.1, Med: 22.27, Max: 40.41
Current: 20.61
11.1
40.41
3-Year Total Revenue Growth Rate 7.10
3-Year Revenue Growth Rate ranked higher than
65.44% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
CBM: 5.9
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -18.1, Med: 4.5, Max: 16
Current: 5.9
-18.1
16
3-Year Total EBITDA Growth Rate 5.40
3-Year EBITDA Growth Rate ranked higher than
78.30% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
CBM: 4.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -26.4, Med: 12, Max: 113
Current: 4.2
-26.4
113
3-Year EPS w/o NRI Growth Rate 16.30
3-Year EPS w/o NRI Growth Rate ranked higher than
67.23% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
CBM: 16.3
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 16.5, Max: 302.1
Current: 16.3
0
302.1

» CBM's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:CBM

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2834
Compare NAS:ESPR TSE:4565 NAS:CHRS NAS:GOSS NAS:RUBY NAS:ALEC NAS:INVA SHSE:603718 NAS:MDGL XKRX:298380 SZSE:002030 NAS:ZLAB NAS:AIMT SZSE:002287 NAS:FATE NAS:TPTX NAS:APLS NAS:ORTX XMAD:ROVI NAS:CORT
Traded in other countries XBX.Germany
Address One Meadowlands Plaza, East Rutherford, NJ, USA, 07073
Cambrex is a biotechnology company focused on developing and commercializing new and generic therapeutics. The company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. Cambrex's portfolio growth strategy has a particular focus on the later stages of the clinical trial process. It also works to secure long-term supply agreements to produce active pharmaceutical ingredients and intermediates for newly approved drug products. Additionally, Cambrex sometimes works with partners to codevelop portfolios of niche generic drug products in finished dosage form.

Ratios

Current vs industry vs history
PE Ratio (TTM) 17.81
PE Ratio ranked higher than
73.79% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
CBM: 17.81
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 5.36, Med: 16.77, Max: 59.25
Current: 17.81
5.36
59.25
Forward PE Ratio 19.01
Forward P/E ranked lower than
53.25% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
CBM: 19.01
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 17.73
PE without NRI ranked higher than
74.49% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
CBM: 17.73
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 5.32, Med: 16.43, Max: 94.8
Current: 17.73
5.32
94.8
Price-to-Owner-Earnings 21.05
Price-to-Owner-Earnings ranked higher than
60.00% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
CBM: 21.05
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 7.43, Med: 23.56, Max: 364.38
Current: 21.05
7.43
364.38
PB Ratio 2.13
PB Ratio ranked higher than
58.21% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CBM: 2.13
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.61, Med: 2.44, Max: 5.9
Current: 2.13
0.61
5.9
PS Ratio 2.55
PS Ratio ranked higher than
79.06% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
CBM: 2.55
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.18, Med: 1.72, Max: 4.26
Current: 2.55
0.18
4.26
Price-to-Free-Cash-Flow 28.06
Price-to-Free-Cash-Flow ranked higher than
57.24% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
CBM: 28.06
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 4.87, Med: 18.19, Max: 74.45
Current: 28.06
4.87
74.45
Price-to-Operating-Cash-Flow 13.00
Price-to-Operating-Cash-Flow ranked higher than
75.71% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
CBM: 13
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 2.92, Med: 11.86, Max: 63.93
Current: 13
2.92
63.93
EV-to-EBIT 16.92
EV-to-EBIT ranked higher than
70.50% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CBM: 16.92
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 6.7, Med: 12.1, Max: 20.2
Current: 16.92
6.7
20.2
EV-to-EBITDA 11.95
EV-to-EBITDA ranked higher than
70.46% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CBM: 11.95
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 3.7, Med: 8.5, Max: 15.5
Current: 11.95
3.7
15.5
EV-to-Revenue 3.33
EV-to-Revenue ranked higher than
82.23% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
CBM: 3.33
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.6, Med: 1.9, Max: 4.4
Current: 3.33
0.6
4.4
PEG Ratio 0.97
PEG Ratio ranked higher than
86.09% of 115 companies
in the Biotechnology industry.
Industry Max: 99.55, Med: 2.02, Min: 0.06
CBM: 0.97
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.43, Med: 1.02, Max: 13
Current: 0.97
0.43
13
Shiller PE Ratio 24.52
Shiller PE Ratio ranked higher than
56.98% of 86 companies
in the Biotechnology industry.
Industry Max: 11472.38, Med: 42.91, Min: 0.02
CBM: 24.52
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 2.83, Med: 33.67, Max: 435.33
Current: 24.52
2.83
435.33
Current Ratio 2.96
Current Ratio ranked higher than
56.33% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CBM: 2.96
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.9, Med: 2.63, Max: 5.23
Current: 2.96
0.9
5.23
Quick Ratio 2.01
Quick Ratio ranked higher than
50.37% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CBM: 2.01
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.5, Med: 1.44, Max: 4.55
Current: 2.01
0.5
4.55
Days Inventory 112.37
Days Inventory ranked lower than
55.51% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
CBM: 112.37
Ranked among companies with meaningful Days Inventory only.
N/A
Days Sales Outstanding 52.45
Days Sales Outstanding ranked higher than
52.25% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
CBM: 52.45
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 49.84, Med: 68.95, Max: 100.38
Current: 52.45
49.84
100.38
Days Payable 52.93
Days Payable ranked lower than
55.97% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
CBM: 52.93
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 37.86, Med: 50.21, Max: 63.55
Current: 52.93
37.86
63.55

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.90
3-Year Share Buyback Rate ranked higher than
87.86% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CBM: -1.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -15.9, Med: -1.8, Max: 4.9
Current: -1.9
-15.9
4.9

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.16
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
64.77% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
CBM: 1.16
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.7, Med: 1.99, Max: 46.39
Current: 1.16
0.7
46.39
Price-to-DCF (Earnings Based) 0.62
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked higher than
65.79% of 38 companies
in the Biotechnology industry.
Industry Max: 12.19, Med: 1.7, Min: 0.43
CBM: 0.62
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.48, Med: 1.82, Max: 2.59
Current: 0.62
0.48
2.59
Price-to-Median-PS-Value 1.48
Price-to-Median-PS-Value ranked lower than
86.87% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
CBM: 1.48
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.09, Med: 0.78, Max: 5.39
Current: 1.48
0.09
5.39
Price-to-Peter-Lynch-Fair-Value 0.85
Price-to-Peter-Lynch-Fair-Value ranked higher than
85.94% of 64 companies
in the Biotechnology industry.
Industry Max: 13.37, Med: 1.72, Min: 0.02
CBM: 0.85
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.49, Med: 1.01, Max: 8.25
Current: 0.85
0.49
8.25
Earnings Yield (Joel Greenblatt) % 5.91
Earnings Yield (Greenblatt) ranked higher than
92.97% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CBM: 5.91
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 5, Med: 8.3, Max: 14.8
Current: 5.91
5
14.8
Forward Rate of Return (Yacktman) % 24.10
Forward Rate of Return ranked higher than
84.44% of 135 companies
in the Biotechnology industry.
Industry Max: 107.61, Med: 11.41, Min: -475.79
CBM: 24.1
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -35, Med: 13.5, Max: 24.5
Current: 24.1
-35
24.5

More Statistics

Revenue (TTM) (Mil) $ 550.45
EPS (TTM) $ 2.34
Beta 2.34
Volatility % 50.57
52-Week Range $ 33.8 - 69.43
Shares Outstanding (Mil) 33.66

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N